Analysis of safety from a human clinical trial with pterostilbene
Daniel M Riche, Corey L McEwen, Krista D Riche, Justin J Sherman, Marion R Wofford, David Deschamp, Michael Griswold, Daniel M Riche, Corey L McEwen, Krista D Riche, Justin J Sherman, Marion R Wofford, David Deschamp, Michael Griswold
Abstract
Objectives. The purpose of this trial was to evaluate the safety of long-term pterostilbene administration in humans. Methodology. The trial was a prospective, randomized, double-blind placebo-controlled intervention trial enrolling patients with hypercholesterolemia (defined as a baseline total cholesterol ≥200 mg/dL and/or baseline low-density lipoprotein cholesterol ≥100 mg/dL). Eighty subjects were divided equally into one of four groups: (1) pterostilbene 125 mg twice daily, (2) pterostilbene 50 mg twice daily, (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily, and (4) matching placebo twice daily for 6-8 weeks. Safety markers included biochemical and subjective measures. Linear mixed models were used to estimate primary safety measure treatment effects. Results. The majority of patients completed the trial (91.3%). The average age was 54 years. The majority of patients were females (71%) and Caucasians (70%). There were no adverse drug reactions (ADRs) on hepatic, renal, or glucose markers based on biochemical analysis. There were no statistically significant self-reported or major ADRs. Conclusion. Pterostilbene is generally safe for use in humans up to 250 mg/day.
Figures
References
- Ferrières J. The French paradox: lessons for other countries. Heart. 2004;90(1):107–111.
- Das DK, Sato M, Ray PS, et al. Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs under Experimental and Clinical Research. 1999;25(2-3):115–120.
- Lin HS, Yue BD, Ho PC. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomedical Chromatography. 2009;23(12):1308–1315.
- Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemotherapy and Pharmacology. 2011;68:593–601.
- Asensi M, Medina I, Ortega A, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biology and Medicine. 2002;33(3):387–398.
- Remsberg CM, Yáñez JA, Ohgami Y, Vega-Villa KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytotherapy Research. 2008;22(2):169–179.
- Nutakul W, Sobers HS, Qiu P, et al. Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: a side-by-side comparison. Journal of Agricultural and Food Chemistry. 2011;59(20):10964–10970.
- Rimando AM, Nagmani R, Feller DR, Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor α-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. Journal of Agricultural and Food Chemistry. 2005;53(9):3403–3407.
- Pan Z, Agarwal AK, Xu T, et al. Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. BMC Medical Genomics. 2008;1, article 7
- Mizuno CS, Ma G, Khan S, Patny A, Avery MA, Rimando AM. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARα . Bioorganic and Medicinal Chemistry. 2008;16(7):3800–3808.
- U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: frequently asked questions about GRAS. 2011 .
- Hougee S, Faber J, Sanders A, et al. Selective COX-2 inhibition by a Pterocarpus marsupium extract characterized by pterostilbene, and its activity in healthy human volunteers. Planta Medica. 2005;71(5):387–392.
- Gottumukkala VS, Masna M, Hindupur RM, Thatipally S. Inventors, aptuit laurus private limited, assignee. X. World patent WO, 2010/0101578 A2, 2009.
- Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrology Dialysis Transplantation. 2001;16(6, article 1301)
- McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, White CM. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. Journal of the American Medical Association. 2004;291(2):216–221.
- Henyan NN, Riche DM, Pitcock JJ, Strickland DC. Marked transaminase elevations and worsening glycemic control associated with counterfeit polyherbal use in a patient with diabetes. Journal of Pharmacy Practice. 2009;22(6):600–605.
Source: PubMed